<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02749825</url>
  </required_header>
  <id_info>
    <org_study_id>PUI-02809</org_study_id>
    <nct_id>NCT02749825</nct_id>
  </id_info>
  <brief_title>Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer</brief_title>
  <official_title>A Multicenter, Randomized Clinical Investigation of Trelstar Versus Continued Therapy in Patients Receiving Lupron or Zoladex for Advanced Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmatech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Manyak, Michael, M.D.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Watson Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pharmatech</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study looks at Testosterone levels in patients receiving Trelstar versus those
      receiving Lupron or Zoladex. These drugs have been approved for treatment of Prostate Cancer
      by the FDA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who are currently receiving Lupron or Zoladex will be consented and then randomized
      to receive either continued treatment with the drug they have been on, or will be randomized
      to Trelstar for a period of 3 months. At the end of that period, testosterone and prostate
      serum antigen (PSA) levels will be drawn and compared to their previous levels to determine
      if Trelstar is as effective as the previous treatment.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Withdrawal of funding support
  </why_stopped>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maintenance of serum testosterone at or below castration level (50ng/dL)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Primary efficacy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum testosterone level at end of study</measure>
    <time_frame>Week 12</time_frame>
    <description>Secondary efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum testosterone from baseline to end of study</measure>
    <time_frame>Baseline and week 12</time_frame>
    <description>Secondary efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Treatment tolerability</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Trelstar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Per prescribing information</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lupron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Per prescribing information</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zoladex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Per prescribing information</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trelstar</intervention_name>
    <description>As labeled</description>
    <arm_group_label>Trelstar</arm_group_label>
    <other_name>Triptorelin pamoate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lupron</intervention_name>
    <description>As labeled</description>
    <arm_group_label>Lupron</arm_group_label>
    <other_name>luprolide acetate for depot suspension</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoladex</intervention_name>
    <description>As labeled</description>
    <arm_group_label>Zoladex</arm_group_label>
    <other_name>goserelin acetate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced Prostate Cancer

          -  Currently taking Lupron or Zoladex

          -  Stable PSA

          -  Baseline testosterone below castration level

          -  Life expectancy &gt; 6 months

          -  Eastern Cooperative Oncology Group performance status of 0-2

          -  Signed, approved informed consent.

        Exclusion Criteria:

          -  Known hypersensitivity to any leuteinizing hormone releasing hormone (LHRH) agonist

          -  Ongoing therapy with hyperprolactinemic agents

          -  Antiandrogen therapy within 28 days prior to study start

          -  Prior Orchiectomy, hypophysectomy or adrenalectomy

          -  Chemotherapy, radiotherapy, or prostatectomy within 28 days prior to study start

          -  Use of any investigational agent 3 months prior to enrollment

          -  Use of systemic corticosteroids within 28 days or during study

          -  Other malignancies within 2 yrs prior to study start, except curatively treated skin
             cancers

          -  Severe kidney or liver failure, based on adequate lab values

          -  Other medical conditions which would be likely to interfere with compliance or
             completion of study requirements
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Michael Manyak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Georege Washington University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Urologic Specialists</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712-5803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heritage Physician Group - Urology Department</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Oncology of the Central Valley</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Bernardino Urological Associates Medical Group</name>
      <address>
        <city>San Bernardino</city>
        <state>California</state>
        <zip>92404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UroSearch</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott A Slavis, MD, PC</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaukat M Qureshi, MD</name>
      <address>
        <city>Pennsville</city>
        <state>New Jersey</state>
        <zip>08070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brooklyn Heights Urology Associates</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jazrawi-Atallah, P.C.</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albemarle Urology Clinic, PA</name>
      <address>
        <city>Albemarle</city>
        <state>North Carolina</state>
        <zip>28001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raj P. Chopra MD, PC</name>
      <address>
        <city>Bloomsburg</city>
        <state>Pennsylvania</state>
        <zip>17815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.pharmatech.com</url>
    <description>Pharmatech - The Research Link website</description>
  </link>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2012</study_first_submitted>
  <study_first_submitted_qc>April 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2016</study_first_posted>
  <last_update_submitted>April 20, 2016</last_update_submitted>
  <last_update_submitted_qc>April 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate</keyword>
  <keyword>Cancer</keyword>
  <keyword>Trelstar</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

